UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 20 November 2025, London UK
TESARO, a GSK subsidiary, initiates litigation against AnaptysBio,
Inc.
GSK plc (LSE/NYSE: GSK) subsidiary, TESARO, Inc., confirms it has
initiated litigation against AnaptysBio, Inc. in the Delaware
Chancery Court. This action contends that recent conduct by
AnaptysBio is in material breach of the existing license agreement
with TESARO regarding the oncology
treatment Jemperli (dostarlimab). The breach entitles TESARO to
terminate the current license agreement, obtain a perpetual and
irrevocable license to dostarlimab, and to reduce the royalties and
milestone payments due by TESARO to AnaptysBio by
50%.
TESARO has initiated this litigation following allegations made by
AnaptysBio that TESARO has not fulfilled certain requirements of
the license agreement entered in March 2014 and that AnaptysBio
intends to revoke TESARO's licence for dostarlimab. GSK and TESARO
are firmly of the view that these allegations are entirely without
merit.
Jemperli is
currently approved in over 35 countries for use in certain
endometrial cancers, the most common gynaecologic cancer in the
United States. GSK and TESARO have reported significant growth
for Jemperli driven
by label expansions in endometrial cancer, including in the US and
EU. A robust and ambitious clinical trial programme to evaluate the
potential use of dostarlimab in additional cancers, including
rectal, colon and head and neck, is ongoing.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q3 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
21, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|